The price of cancer drugs is too high, an increasingly significant issue in U.S. health care expenditures. In this op-ed for the Washington Post, Hagop Kantarjian, scholar in health policy, explains how to reduce the price of cancer drugs.
John W. Diamond , George Zodrow
Sep 15 2020 | Center for Public Finance
Quianta Moore , Christopher F. Kulesza
Sep 11 2020 | Child Health Policy